Drug type could offer a new approach to treating a number of cancers with PBRM1 mutations
News
FDA approves GSK’s Jemperli for dMMR endometrial cancer
PD-1 inhibitor approved to treat patients with specific biomarker
BMS to invest in new cell therapy manufacturing site in Europe
Construction on Leiden, Netherlands site anticipated to begin later this year
MHRA authorises Amarin’s heart drug Vazkepa
Drug demonstrated a 25% relative risk reduction in the first occurrence of major adverse cardiovascular events in REDUCE-IT trial
Less than 1 month until CROY 2021 closes for entry
The 2021 Clinical Researcher of the Year – The Americas will be closing for entry on the 14th of May.
Lilly, Incyte report positive results for baricitinib in alopecia areata
Oral JAK inhibitor improved hair regrowth across both dosing groups
New report suggests the gender pay gap for doctors increased during pandemic
Medscape survey finds female doctors reported 30% lower pay compared to male doctors
Novo Nordisk plans study of oral semaglutide in obesity
Study will include approximately 1,000 people with obesity or overweight with comorbidities
NHS leaders warn of a ‘chronic undersupply’ of staff
Six organisations representing most of the NHS workforce pen joint letter calling for action
GW Pharma’s Epidyolex scores new EU indication
Cannabis-based medicine approved for the treatment of seizures associated with tuberous sclerosis complex
J&J resumes roll-out of COVID-19 vaccine in EU
EMA’s safety committee has confirmed the overall benefit-risk profile of the jab
Novartis’ MS therapy Kesimpta wins NICE backing
First self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS
UK government launches search for at-home COVID-19 treatments
Antivirals Taskforce established in a bid to identify promising at-home antiviral medicines
Real-world data suggests Sputnik V vaccine is 97.6% effective, says RDIF
Data comes from 3.8 million Russians vaccinated with COVID-19 vaccine
Breakthrough designation granted for Amgen’s bemarituzumab
Amgen gained access to bemarituzumab as part of its acquisition of Five Prime Therapeutics
